Nuvation Bio Inc. (NUVB) Stock
8 of the hedge funds AlphaScala tracks reported NUVB in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Duquesne Family Office's at $25.79M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 5, 2026.
Which hedge funds own NUVB?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Duquesne Family Office Stanley Druckenmiller | 4.54M | $25.79M | n/a |
| Citadel Ken Griffin | 1.99M | $11.29M | -4% |
| Renaissance Technologies Jim Simons (founder) | 1.35M | $7.65M | +141% |
| D.E. Shaw David Shaw | 1.14M | $6.48M | +190% |
| Millennium Management Israel Englander | 373K | $2.12M | -67% |
| Hussman Investment Trust John Hussman | 210K | $1.18M | NEW |
| Marshall Wace | 83K | $473.7K | -19% |
| Greenlight Capital David Einhorn | 35K | $198.8K | n/a |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Nuvation Bio Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 19, 26 | Hattersley Gary | CHIEF SCIENTIFIC OFFICER | SELL | 100.0K | $709K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →NUVB price chart
Powered by TradingViewWhat does Nuvation Bio Inc. do?
Nuvation Bio Inc. is a biopharmaceutical company focused on developing innovative therapies for oncology patients. Its primary purpose is to research and advance novel drug candidates targeting various forms of cancer, particularly those for which few treatments currently exist. The company's pipeline is centered on next-generation therapies, including small molecules and targeted drugs designed to enhance and extend the lives of cancer patients. Operating in the highly competitive and scientifically rigorous field of biotechnology, Nuvation Bio Inc. collaborates with leading experts in oncological research to bring promising treatments to clinical trials. Its strategic focus on areas like neuroendocrine tumors and advanced prostate cancer highlights its dedication to addressing unmet medical needs. In the financial markets, Nuvation Bio Inc. holds significance due to its potential impact on the healthcare sector, particularly through the development of breakthrough cancer therapies that could transform treatment paradigms. The company's progress is closely followed by investors and stakeholders interested in the future of cancer treatment innovation.